Bill > HR6320

This bill, called the "Improving Medicaid Precision and Cancer Test Act of 2025", aims to require Medicaid to cover lung cancer biomarker testing starting January 1, 2027. Biomarker testing is a medical procedure that analyzes specific molecular characteristics of a patient's cancer to help doctors better understand the disease and develop more targeted treatment plans. The bill modifies existing Social Security Act provisions by adding lung cancer biomarker testing as a required service under Medicaid, specifically by amending sections 1902, 1905, and 1937. These technical amendments essentially mandate that state Medicaid programs include lung cancer biomarker testing as a covered benefit, ensuring that Medicaid beneficiaries with lung cancer can access this important diagnostic tool without additional out-of-pocket costs. The changes will be implemented systematically, with full coverage requirement taking effect on January 1, 2027, which allows time for state Medicaid programs to adjust their coverage policies and systems.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/6320/all-info